glp 1 for autoimmune disease GLP-1 Medications Arthritis & The anti-inflammatory and immunological properties
Description
Not significantly
This places the candidate closer to the efficacy range of Novo Nordisks semaglutide and Eli Lillys tirzepatide, both dominant players in the obesity market
Although the trial did not show a significant advantage in reducing cardiovascular events [6], or hospitalizations, it provided insights into liraglutides safety and tolerability in this patient population [6]
J., Dehlendorff, C., & Mrch, L
Neither number has been independently verified by this publication - both should be treated as brand-stated
doi: 10.2147/DMSO.S253097 182 ScottLJ
